🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the infection, according to health experts.

An International Challenge

Cases of gonorrhoea are on the rise worldwide, with figures suggesting more than 82 million new cases per year. Particularly high rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This treatment, which is employed against urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This approval marks a significant shift in the therapy of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Data and Worldwide Availability

As per results detailed in a major medical journal, zoliflodacin eradicated the vast majority of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which involves an injection and a pill. The study included nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have voiced hope. Access to a one-pill regimen such as this is described as a "critical tool" for public health efforts. This is considered essential to reduce the burden of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea globally.